Accountability
Abbott Nutrition reopens Michigan baby formula plant amid shortage
Abbott Nutrition has restarted production at the Michigan baby formula factory that has been closed for months due to contamination, the company said Saturday, taking a step toward easing a nationwide supply shortage expected to persist into the summer.
The company said in a statement it was resuming production at the Sturgis, Michigan facility “after meeting initial requirements agreed to with the U.S. Food and Drug Administration as part of the consent decree entered into on May 16.” Abbott is one of just four companies that produce about 90% of U.S. formula.
The February shutdown of the largest formula factory in the country led to the supply problems that have forced some parents to seek formula from food banks, friends and doctor’s offices.
Abbott said it initially will prioritize production of its EleCare specialty formulas for infants with severe food allergies and digestive problems who have few other options for nutrition. The company said it will take about three weeks before new formula from the plant begins getting to consumers.
“We will ramp production as quickly as we can while meeting all requirements,” Abbott said in a statement.
The plant’s reopening is one of several federal actions that are expected to improve supplies in the weeks ahead. President Joe Biden’s administration has eased import rules for foreign manufacturers, airlifted formula from Europe and invoked federal emergency rules to prioritize U.S. production.
Abbott closed the Sturgis, Michigan, factory in February after the Food and Drug Administration began investigating four bacterial infections among infants who consumed powdered formula from the plant. Two of the babies died. The company continues to state that its products have not been directly linked to the infections, which involved different bacterial strains.
FDA inspectors eventually uncovered a host of violations at the plant, including bacterial contamination, a leaky roof and lax safety protocols. The FDA has faced intense scrutiny for taking months to close the plant and then negotiate its reopening. Agency leaders recently told Congress they had to enter a legally binding agreement with Abbott to assure all the problems were fixed.
Terry A. Hurlbut has been a student of politics, philosophy, and science for more than 35 years. He is a graduate of Yale College and has served as a physician-level laboratory administrator in a 250-bed community hospital. He also is a serious student of the Bible, is conversant in its two primary original languages, and has followed the creation-science movement closely since 1993.
-
Executive3 days ago
Analysis: California’s Shift to the Right Lost on Newsom
-
Constitution3 days ago
The Deep State Ten-point Cleanse
-
Human Interest4 days ago
The Blame Games begin
-
Civilization2 days ago
Unprofessional conduct
-
Civilization5 days ago
Philadelphia: A Republican Win, Electoral Gains and a Path Forward
-
Clergy5 days ago
It Pleased The Lord To Bruise Him!
-
Civilization1 day ago
FEMA aid withholding – policy?
-
Civilization3 days ago
Diminishing ‘The Endarkenment’